Nilesh27:
@harsh.beria93 are you trackking ddev plastics, last year got de-merged. Company is into making plastic compounds like cables, footwares, emginnered plastics for automobile, appliances, electronics etc. Clients are KEI, finolex, havells.
I am sorry, I haven’t done much work on ddev.
I follow a relatively simple selling strategy:
Incorrect assessment of business (e.g. exits made in Lupin , Shemaroo , etc.)
Well priced (when expected IRRs < 10%). I am very stringent with this criteria and have made timely exits in a lot of cos (e.g. Balkrishna Ind., HCL Tech , Infy, IEX , Maithan alloys , Nalco , Natco , etc.).
Switch to another company that offers significantly higher IRRs (e.g. switch from Mahindra Logistics to NALCO in April 2020, switch from Divis to Cadila in July 2020, swit…
I dont use stop loss or any share price based criterion to exit stocks.
riken_shah:
not much clarity on relation and dependcy with SKant group
not much information available on internet about SKant groups.
Skant is a formulations co whereas Anuh manufactures API. There is a lot of information on their group website and their respective rating reports. I have shared some of these on Anuh Pharma thread.
I am sharing my work on entities related to the Anuh Pharma group.
The 4 main group cos operating in pharma sector are Anuh Pharma (listed co), Eskay Iodine (operates in iodine based APIs), S Kant Healthcare (formulations business in Africa), and Eskay Speciality (specialty chemical business).
[image]
Eskay Iodine
Manufactures iodine based chemicals and has low operating margins (5-9% OPM)
Benefitted from higher iodine prices, grown very well in 2022
In terms of scale, they are smaller tha…
8 Likes
